Market for Impact

Summary

What do they do? Harm Reduction Therapeutics Inc (EIN82-2380699) is the nonprofit manufacturer, distinct from Remedy Alliance and Harm Reduction Therapy Center. The public financial-support contact is not a retail checkout or verified restricted free-dose offer. No inquiry or gift was submitted. More

Why this approach interests us

HRT explicitly accepts philanthropic support for free supply, lower prices and production capacity; current partners distribute its approved OTC naloxone.

Our main reservations

No verified current marginal price, free-dose queue, linked-person reach or causal rescue increment. Existing free supply and public naloxone may replace most nominal output.

What do you get for your dollar?

Central national estimate: $255,604 donor and $357,846 gross-associated resources per10 QALYs. Bay estimates are $25,560,427 and $35,784,598; SF $127,802,137 and $178,922,991. Local shares are weak priors, not identified local results. Inspect formulas, inputs and sources.

whole gift: $100,000 — 70% free-access supply,20% price/capacity/working capital,10% partnership/other work: judgment allocations. All costs retained.
finite national net health: 3.912297655 QALYs — 245 expected unique people; one protection year; ten-year survival comparison; not245 rescues or lives saved.
favorable national case: $3,293 donor / $4,939 resources — Joint favorable assumptions, not a confidence bound or verified open opportunity.

1. What do they do?

Harm Reduction Therapeutics Inc (EIN82-2380699) is the nonprofit manufacturer, distinct from Remedy Alliance and Harm Reduction Therapy Center. The public financial-support contact is not a retail checkout or verified restricted free-dose offer. No inquiry or gift was submitted.

Whole-gift portfolio

Allocate all charitable cash. Credit only assumed incremental free-access supply; retain other capacity and partnership costs without separate health credit.

Supply and placement

Subtract replacement of existing commitments, inventory, paid orders and other funding, apply capacity caps, then high-risk placement and a pooled packs-per-unique-person allowance.

Finite causal health

Compare the same people under baseline and temporarily improved effective rescue, integrating their survival difference once.

Scope of this review. One twin pack=two single-use3mg devices;24packs/case. Packs_per_unique_person is pooled supply per unique at-risk beneficiary over the funded interval, not a clinical dose recommendation, one rescuer=one patient, or one package=one overdose. Whole gift fractions sum1. Free-access cash price includes core manufacturer logistics/admin once. Remaining capital/price-access/partnership budget retained with no quantified additional health; not another same-core overhead haircut. Funding additionality subtracts substitution of already-financed free production, existing inventory, paid orders and other funders. Manufacturing cap limits extra output. Low inventory price alone does not imply supply bottleneck. Placement is last-mile arrival in high-risk networks. Packs per unique beneficiary absorbs repeated issues/sharing and stock per beneficiary; it is an unverified linked-person planning prior. Repeated responses do not generate another survivor tail. Both scenarios begin with the same unique at-risk people alive at intervention start. Delay discounts only. Recurrent nonfatal overdose leaves the person alive; fatal opioid hazard=event rate*fatality without effective rescue*(1-effective rescue). Other mortality is separate. Improved effective rescue only during finite funded protection; afterward both arms return to identical baseline mortality. Integrate the difference in whole-person survival once to finite horizon. No lifetime rescue multiplier, reduced drug use, MOUD or brain injury benefit. Effective rescue already includes witnesses, working supply, correct use, EMS and alternative naloxone; no separate98% observed-survival or formulation-efficacy factor. Rescue increment may be negative in a diagnostic access-displacement scenario. Positive incremental-dose demand is constrained not to exceed the available device pool; assumed devices per response is a modeling budget, not medical advice. HRT manufacturing and Remedy distribution estimates are alternative marginal-gift counterfactuals, not additive claims on the same naloxone chain. Distribution capacity is held at existing baseline for HRT. A combined portfolio must assign each linked person's incremental survival once; published HRT+Remedy QALYs cannot simply be summed. Gross associated outside costs per nominal pack cover only downstream distribution/training/storage/participant inputs not already HRT-paid. Full gift plus outside allowance retained even at supply null; not exhaustive net societal cost. No double production or shipping charge, medical savings or free-stock retail valuation. Signed rescue effect and gift-date PV harms allowed. Per-person acute harm is separate from survival utility; independent harm remains at zero activity. Positive ratios are null at zero/negative Q or nonfinite ratio. Bay/SF central shares1%/.2% are weak explicit national-program beneficiary-residence priors, not observed allocation or headquarters location. Nested0<=SF<=Bay<=US. Local-zero and larger-local scenarios expose uncertainty. National survival assumptions are not validated region-specific hazards.

2. Monitoring and information sharing

RiVive3mg nasal naloxone

FDA OTC approval. Supports opioid-overdose rescue action.

Our assessment. No manufacturer marginal deaths-per-pack or product superiority estimate.

19 selected Pennsylvania interviewees, variable denominators

Manufacturer-commissioned compensated qualitative interviews. Acceptability and reported experiences; no randomized mortality comparison.

Our assessment. No dose-use, unique-person, fatality or lower-withdrawal causal coefficient imported.

People after nonfatal opioid overdose

Historical adult Medicaid cohort. Repeat295/1,000person-years and fatal overdose1,154/100,000person-years; separate study all-cause778.3/10,000person-years.

Our assessment. Context for recurrent risk only. Model other mortality excludes overdose; cohorts are not current HRT or region-specific estimates.

Historical Massachusetts overdose-education/naloxone communities

Community interrupted time series. Mortality associations support plausibility.

Our assessment. Observational association not imported as individual rescue probability.

California statewide eligible distribution partners

Current DHCS public program documentation. Existing free nasal/injectable supply; generic nasal switch April2026.

Our assessment. Competing effective rescue and supply replacement, not absence of care.

3. Qualitative assessment

HRT explicitly accepts philanthropic support for free supply, lower prices and production capacity; current partners distribute its approved OTC naloxone.

Key reservations

Current $30 cost,70% allocation,35% supply additionality,60% placement and8pp rescue increment are unverified priors.
No current free-dose queue or actual unique linked beneficiaries; central geography1% Bay/.2% SF is particularly weak.
2024 return shows $5,000 contributions and substantial sales; historic donor reliance is not evidence ordinary gifts fund all current production.
Reported PF operating expense $8,244,357 excludes $4,658,446 COGS. Combined $12,902,803 differs by $1 from reported direct charitable activity. No annual quantity permits current pack-cost inference.
HRT and Remedy health must not be added for shared people or stock.
Gross-associated resource allowance excludes unmeasured future medical and other budgets; no net societal ranking claim.

Benefits not included in our estimate

Price subsidy, manufacturing expansion and partnerships outside the credited supply tranche: costs retained, health unquantified.
No credit for historical product development, existing10% donation commitment, distributed inventory alone, or self-reported reversal counts.
No lifetime survival, reduced drug use, MOUD, infection, brain injury or speculative formulation-superiority credit.

4. What do you get for your dollar?

Expected unique-person survival, not deaths per pack

All clinical conversion and marginal funding values are explicit judgments. FDA approval supports the pharmacologic mechanism, not manufacturer-specific effectiveness. Existing public stock and EMS enter baseline rescue; funding substitution is separately handled upstream.

A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.

How we calculate the estimate

Whole-gift causal chain: N=min(min(D*a/c*f,packCap)*placement/packsPerPerson,personCap); h0=other+events*fatality*(1-rescue0); Δh=events*fatality*Δrescue; Q=N*u/(1+d)^delay*∫₀ᴴ[exp(-h0*t+Δh*min(t,A))-exp(-h0*t)]/(1+d)^t dt − PV harms
N=245 expected people; national Q=3.912297655; gross resources=$140,000.

Model inputs and assumptions

gift usd: 100000 (range: Reference gift; scalable only within assumed caps). Ordinary unrestricted gift; entire gift retained in every numerator. Judgment / explicit prior.
free access allocation: 0.7 (range: See signed scenarios and calculator validation domain). 70% judgment: free supply is a stated philanthropic purpose, but allocation is not a verified earmark. 30–90% scenario range. Judgment / explicit prior.
other capacity allocation: 0.2 (range: See signed scenarios and calculator validation domain). 20% judgment for price access, working capital and manufacturing capacity; health unquantified, costs retained. Judgment / explicit prior.
other partnership allocation: 0.1 (range: See signed scenarios and calculator validation domain). 10% judgment for partnerships and other portfolio work; health unquantified, costs retained. Judgment / explicit prior.
cash per twin pack: 30 (range: See signed scenarios and calculator validation domain). $30 planning prior, not current quote. Initial $36 is explicitly now lower; $20–45 stress range includes future full-cost uncertainty. Core production/admin/logistics included once. Judgment / explicit prior.
funding additionality: 0.35 (range: See signed scenarios and calculator validation domain). 35% prior: most nominal funding can replace sales, other donors, existing inventory or baseline free commitment; 0–70% scenarios. Judgment / explicit prior.
max additional twin packs: 5000 (range: See signed scenarios and calculator validation domain). 5,000 additional-pack cap is a planning constraint, not verified open manufacturing capacity. Judgment / explicit prior.
high risk placement: 0.6 (range: See signed scenarios and calculator validation domain). 60% prior: downstream partners must actually place supply in high-risk networks, not simply warehouse it; 0–80% scenarios. Judgment / explicit prior.
twin packs per unique person: 2 (range: See signed scenarios and calculator validation domain). Two twin packs per unique at-risk person is a pooled four-device planning allowance, not observed recipients or dosing guidance; 1–6 scenarios. Judgment / explicit prior.
max unique people: 1000 (range: See signed scenarios and calculator validation domain). 1,000-person planning cap, not observed queue or recipient count. Judgment / explicit prior.
events per person year: 0.5 (range: See signed scenarios and calculator validation domain). 0.5 annual events is a high-risk cohort judgment; historical Medicaid recurrence 0.295/year is context, not current RiVive evidence. Judgment / explicit prior.
fatality without effective rescue: 0.1 (range: See signed scenarios and calculator validation domain). 10% counterfactual event-fatality prior, not observed fatality among treated survivors. Judgment / explicit prior.
baseline effective rescue: 0.8 (range: See signed scenarios and calculator validation domain). 80% effective rescue already available through other stock, EMS and rescuers; current public supply prevents a no-care baseline. Judgment / explicit prior.
rescue increment: 0.08 (range: See signed scenarios and calculator validation domain). Eight percentage points is the incremental probability of effective rescue per event during protection, including event-time availability and use. Signed -5pp failure and +15pp favorable cases. Judgment / explicit prior.
mean doses per incremental response: 2 (range: See signed scenarios and calculator validation domain). Two devices per incremental response is a device-budget prior, not product-specific measured consumption or clinical advice. Judgment / explicit prior.
other mortality hazard: 0.06 (range: See signed scenarios and calculator validation domain). 0.06/year is an other-cause hazard prior. Separate opioid hazard adds 0.01/year centrally; do not add opioid mortality to an all-cause rate. Judgment / explicit prior.
utility: 0.7 (range: See signed scenarios and calculator validation domain). 0.7 surviving-person utility judgment, not a disability-weight estimate for every person using opioids. Judgment / explicit prior.
active years: 1 (range: See signed scenarios and calculator validation domain). One year of funded rescue protection, not ten years of active stock benefit; 0.25–1-year scenarios. Judgment / explicit prior.
horizon years: 10 (range: See signed scenarios and calculator validation domain). Ten-year finite survival observation, with shared baseline mortality after protection. 1–15-year scenarios; no lifetime award. Judgment / explicit prior.
delay years: 0.5 (range: See signed scenarios and calculator validation domain). Half-year service delay; expected cohort is already conditioned on being alive at service start. Delay discounts, not pre-service survival. Judgment / explicit prior.
discount: 0.03 (range: See signed scenarios and calculator validation domain). 3% annual health discount applied continuously via log(1.03). Judgment / explicit prior.
episode harm per unique person: 0.0002 (range: See signed scenarios and calculator validation domain). 0.0002 gift-date present-value QALYs lost per unique person, acute burden separate from surviving-person utility; judgment. Judgment / explicit prior.
independent harm q: 0 (range: See signed scenarios and calculator validation domain). Gift-date present-value harm not tied to activity. Central zero; explicit zero-activity -1 QALY case. Judgment / explicit prior.
outside per nominal pack: 15 (range: See signed scenarios and calculator validation domain). $15 prior for downstream handling, community handoff/training and participant inputs outside manufacturer price; not HRT-paid warehouse, transport or repeat production. Judgment / explicit prior.
outside other usd: 5000 (range: See signed scenarios and calculator validation domain). $5,000 further associated resource allowance. Gross-associated, not exhaustive net societal cost or proven incremental expenditure. Judgment / explicit prior.
bay share: 0.01 (range: See signed scenarios and calculator validation domain). 1% weak beneficiary-residence prior, not Berkeley distributor headquarters or measured shipment allocation. Zero and3% cases. Judgment / explicit prior.
sf share: 0.002 (range: See signed scenarios and calculator validation domain). 0.2% weak beneficiary-residence prior nested in Bay share; zero and0.5% cases. Same national risk mix is not regionally validated. Judgment / explicit prior.

Entire $100,000 gift remains in the price

central: US donor $255,604; US resources $357,846. Net QALYs US 3.912297655, Bay 0.03912297655, SF 0.007824595311. Per10 QALYs: US donor $255,604, resource $357,846; Bay donor $25,560,427, resource $35,784,598; SF donor $127,802,137, resource $178,922,991. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
favorable: US donor $3,293; US resources $4,939. Net QALYs US 303.6930187, Bay 3.036930187, SF 0.6073860375. Per10 QALYs: US donor $3,293, resource $4,939; Bay donor $329,280, resource $493,920; SF donor $1,646,399, resource $2,469,599. Gross-associated cost $150,000. Scenario, not statistical confidence interval.
cautious: US donor $414,336,870; US resources $497,204,244. Net QALYs US 0.002413495084, Bay 0.00002413495084, SF 0.000004826990169. Per10 QALYs: US donor $414,336,870, resource $497,204,244; Bay donor $41,433,687,041, resource $49,720,424,449; SF donor $207,168,435,206, resource $248,602,122,247. Gross-associated cost $120,000. Scenario, not statistical confidence interval.
low_free_access_allocation: US donor $596,410; US resources $715,692. Net QALYs US 1.676698995, Bay 0.01676698995, SF 0.003353397990. Per10 QALYs: US donor $596,410, resource $715,692; Bay donor $59,640,997, resource $71,569,197; SF donor $298,204,986, resource $357,845,983. Gross-associated cost $120,000. Scenario, not statistical confidence interval.
cheaper_current_cost: US donor $170,403; US resources $268,384. Net QALYs US 5.868446483, Bay 0.05868446483, SF 0.01173689297. Per10 QALYs: US donor $170,403, resource $268,384; Bay donor $17,040,285, resource $26,838,449; SF donor $85,201,425, resource $134,192,244. Gross-associated cost $157,500. Scenario, not statistical confidence interval.
higher_full_cost: US donor $383,406; US resources $492,038. Net QALYs US 2.608198437, Bay 0.02608198437, SF 0.005216396874. Per10 QALYs: US donor $383,406, resource $492,038; Bay donor $38,340,641, resource $49,203,823; SF donor $191,703,205, resource $246,019,113. Gross-associated cost $128,333. Scenario, not statistical confidence interval.
public_stock_replacement: US donor No finite positive ratio; US resources No finite positive ratio. Net QALYs US 0.000000000, Bay 0.000000000, SF 0.000000000. Per10 QALYs: US donor No finite positive ratio, resource No finite positive ratio; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
low_supply_additionality: US donor $894,615; US resources $1,252,461. Net QALYs US 1.117799330, Bay 0.01117799330, SF 0.002235598660. Per10 QALYs: US donor $894,615, resource $1,252,461; Bay donor $89,461,496, resource $125,246,094; SF donor $447,307,479, resource $626,230,470. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
last_mile_failure: US donor No finite positive ratio; US resources No finite positive ratio. Net QALYs US 0.000000000, Bay 0.000000000, SF 0.000000000. Per10 QALYs: US donor No finite positive ratio, resource No finite positive ratio; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
many_repeat_packs: US donor $766,813; US resources $1,073,538. Net QALYs US 1.304099218, Bay 0.01304099218, SF 0.002608198437. Per10 QALYs: US donor $766,813, resource $1,073,538; Bay donor $76,681,282, resource $107,353,795; SF donor $383,406,410, resource $536,768,974. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
quarter_year_protection: US donor $999,273; US resources $1,398,982. Net QALYs US 1.000727592, Bay 0.01000727592, SF 0.002001455185. Per10 QALYs: US donor $999,273, resource $1,398,982; Bay donor $99,927,294, resource $139,898,211; SF donor $499,636,468, resource $699,491,056. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
five_year_survival: US donor $436,542; US resources $611,159. Net QALYs US 2.290728612, Bay 0.02290728612, SF 0.004581457224. Per10 QALYs: US donor $436,542, resource $611,159; Bay donor $43,654,233, resource $61,115,926; SF donor $218,271,164, resource $305,579,629. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
one_year_survival: US donor $3,734,541; US resources $5,228,357. Net QALYs US 0.2677705497, Bay 0.002677705497, SF 0.0005355410994. Per10 QALYs: US donor $3,734,541, resource $5,228,357; Bay donor $373,454,064, resource $522,835,690; SF donor $1,867,270,320, resource $2,614,178,448. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
high_baseline_rescue: US donor $1,026,637; US resources $1,437,292. Net QALYs US 0.9740540821, Bay 0.009740540821, SF 0.001948108164. Per10 QALYs: US donor $1,026,637, resource $1,437,292; Bay donor $102,663,704, resource $143,729,186; SF donor $513,318,520, resource $718,645,928. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
high_recurrent_mortality: US donor $84,866; US resources $118,812. Net QALYs US 11.78334528, Bay 0.1178334528, SF 0.02356669056. Per10 QALYs: US donor $84,866, resource $118,812; Bay donor $8,486,554, resource $11,881,176; SF donor $42,432,772, resource $59,405,880. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
no_incremental_rescue: US donor No finite positive ratio; US resources No finite positive ratio. Net QALYs US -0.04900000000, Bay -0.0004900000000, SF -0.00009800000000. Per10 QALYs: US donor No finite positive ratio, resource No finite positive ratio; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Rescue effect null retains acute harm.
true_health_null: US donor No finite positive ratio; US resources No finite positive ratio. Net QALYs US 0.000000000, Bay 0.000000000, SF 0.000000000. Per10 QALYs: US donor No finite positive ratio, resource No finite positive ratio; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Rescue effect and acute harm both null.
signed_rescue_harm: US donor No finite positive ratio; US resources No finite positive ratio. Net QALYs US -2.516994209, Bay -0.02516994209, SF -0.005033988418. Per10 QALYs: US donor No finite positive ratio, resource No finite positive ratio; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Diagnostic target access displacement worsens effective rescue.
independent_harm_zero_activity: US donor No finite positive ratio; US resources No finite positive ratio. Net QALYs US -1.000000000, Bay -0.01000000000, SF -0.002000000000. Per10 QALYs: US donor No finite positive ratio, resource No finite positive ratio; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
limited_manufacturing: US donor $2,087,435; US resources $2,922,409. Net QALYs US 0.4790568558, Bay 0.004790568558, SF 0.0009581137115. Per10 QALYs: US donor $2,087,435, resource $2,922,409; Bay donor $208,743,490, resource $292,240,886; SF donor $1,043,717,450, resource $1,461,204,430. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
limited_unique_reach: US donor $2,504,922; US resources $3,506,891. Net QALYs US 0.3992140465, Bay 0.003992140465, SF 0.0007984280929. Per10 QALYs: US donor $2,504,922, resource $3,506,891; Bay donor $250,492,188, resource $350,689,063; SF donor $1,252,460,940, resource $1,753,445,316. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
double_outside_resources: US donor $255,604; US resources $460,088. Net QALYs US 3.912297655, Bay 0.03912297655, SF 0.007824595311. Per10 QALYs: US donor $255,604, resource $460,088; Bay donor $25,560,427, resource $46,008,769; SF donor $127,802,137, resource $230,043,846. Gross-associated cost $180,000. Scenario, not statistical confidence interval.
no_identified_local_share: US donor $255,604; US resources $357,846. Net QALYs US 3.912297655, Bay 0.000000000, SF 0.000000000. Per10 QALYs: US donor $255,604, resource $357,846; Bay donor No finite positive ratio, resource No finite positive ratio; SF donor No finite positive ratio, resource No finite positive ratio. Gross-associated cost $140,000. Scenario, not statistical confidence interval.
larger_local_share_hypothesis: US donor $255,604; US resources $357,846. Net QALYs US 3.912297655, Bay 0.1173689297, SF 0.01956148828. Per10 QALYs: US donor $255,604, resource $357,846; Bay donor $8,520,142, resource $11,928,199; SF donor $51,120,855, resource $71,569,197. Gross-associated cost $140,000. Scenario, not statistical confidence interval.

Uncertainty. Central estimates are a transparent conditional planning model, not evidence-based confidence intervals. Favorable assumptions move together; zero and harm remain possible. Inventory does not establish use, and expected unique-person counts are not observed.

HRT and Remedy are alternatives along a shared chain

The existing Remedy model uses a representative four-injectable-dose-equivalent distribution bundle, not a RiVive twin pack. Its procurement, last-mile constraints and causal units cannot be copied into this manufacturer model.

Joint-portfolio restriction: Combined health = survival gains for a deduplicated linked-person cohort, not Q(HRT)+Q(Remedy) for overlapping supply
No additive shared-chain benefit claimed.

QALY conversion assumptions

Counterfactual: Existing downstream capacity held fixed (range: Zero last-mile placement to favorable delivery). HRT gift changes supply conditional on baseline partner capacity; Remedy gift changes distribution conditional on its own supply baseline. Neither may receive independent full credit in a joint portfolio for the same person. Explicit boundary.

last_mile_failure: No placement, no supply-linked health. Resources remain. An arbitrary attribution haircut cannot replace specifying the actual bottleneck and joint counterfactual.

Do not sum either report with overlapping local naloxone cohorts. Count manufacturing price once; outside costs here exclude upstream costs already included in that price.

5. Funding and previous grants

Verify a supply-constrained, otherwise-unfunded tranche with downstream delivery and nonduplicated beneficiary exposure before treating favorable scenarios as an actionable opportunity.

No verified current quote or open funding tranche. Whole gift plus outside allowances remain even at null supply. Gross-associated resources include nonadditional downstream activity and are neither exhaustive nor net societal cost. Do not infer manufacture is currently the binding bottleneck.

This review does not establish a verified marginal funding offer or a complete history of grants.

Donate

Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.

6. Sources

2024 Form 990-PF. Harm Reduction Therapeutics / IRS. Primary return identifies HRT Inc EIN82-2380699; rendered public iframe read directly. PF sales revenue is net of COGS; do not mistake reported operating expenses for whole manufacture cost.. Published: Filed November 17, 2025; retrieved: September 8, 2026.
Our Story. Harm Reduction Therapeutics. Current free/low-cost OTC mission, philanthropic pathway; original$36/twin pack now explicitly lower. Not a current dollar quote or restricted ordinary gift offer.. Published: Current undated; retrieved: September 8, 2026.
RiVive FAQ. Harm Reduction Therapeutics. Price includes approximately95% manufacturing/packaging/testing/warehousing/transport plus5% coordination/admin/regulatory costs;24 twinpacks per case; direct free shipping. RA same price; do not charge production twice.. Published: Current undated; retrieved: September 8, 2026.
New distribution partnership. HRT / Capstone Health Alliance. Current national provider-distribution expansion and stated at least10% units donated. Existing commitment is baseline, not marginal philanthropic output.. Published: January 28, 2026 (March upload); retrieved: September 8, 2026.
2025 RiVive Community Feedback Report. HRT / Health Management Associates. 18-page primary manufacturer-commissioned qualitative report read in memory.19 compensated Pennsylvania interviews with variable response denominators; convenience/site selection, no randomized product comparison, dose-use rate or causal mortality estimate.. Published: Released April 2026; retrieved: September 8, 2026.
200,000-dose partnership announcement. Remedy Alliance / HRT. Historical200,000 individual doses (=100,000 twin packs),10% of projected initial annual production. Not a fresh2026 funding offer, observed use or deaths averted.. Published: August 9, 2023; retrieved: September 8, 2026.
HOPE harm reduction kits. Students for Sensible Drug Policy. Primary current partner describes HRT-donated RiVive in free trained-participant kits. Shows actual distribution beyond Remedy, not causal extra doses or local residence.. Published: August 31, 2026; retrieved: September 8, 2026.
Second OTC naloxone nasal spray approval. FDA. RiVive3mg approval and pharmacologic rescue mechanism; not comparative superiority or charity-level deaths-per-pack.. Published: July 28, 2023; retrieved: September 8, 2026.
Naloxone Distribution Project. California DHCS. Free nasal/intramuscular naloxone and existing statewide distribution; prior reversals are not donated-gift lives saved.. Published: Current; retrieved: September 8, 2026.
NDP FAQs. California DHCS. Generic nasal replaces brand Narcan in program; partner training requirements. Existing alternative rescue and inventory remain in counterfactual.. Published: Current; April 2026 product change; retrieved: September 8, 2026.
Risks of fatal opioid overdose after nonfatal overdose. Olfson et al.. Primary historical adult Medicaid cohort: repeat295/1,000person-years; fatal opioid overdose1,154/100,000person-years. Context only, not current fentanyl or HRT recipient hazard.. Published: 2018 article;2023 manuscript availability; retrieved: September 8, 2026.
Causes of death after nonfatal opioid overdose. Olfson et al.. Primary historical cohort: all-cause778.3/10,000person-years. Other-mortality input excludes modeled overdose mortality; not added mechanically to all-cause rate.. Published: 2018; retrieved: September 8, 2026.
Overdose education/naloxone implementation and mortality. Walley et al.. Historical observational community interrupted-time-series association, not randomized individual naloxone or manufacturer marginal effect. No reported mortality ratio imported.. Published: 2013; retrieved: September 8, 2026.

Annual expenses: years and sources

Average annual expenses (three consecutive fiscal years): Not available. Organization size is separate from the modeled cost-effectiveness of a donation.

Harm Reduction Therapeutics

Three years of organization-level expenses have not yet been verified for this report. No other organization or fiscal sponsor budget has been substituted.